FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 324:527-531 February 21, 1991 Number 8 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. The control of hyperphosphatemia is a major clinical problem in patients with chronic renal failure receiving regular dialysis treatment. Despite continuing concern about aluminum toxicity, aluminum-containing antacids are still used in many of these patients as phosphate-binding agents. Although maximal acceptable doses of aluminum hydroxide have been recommended, the safety and efficacy of these guidelines have not been evaluated. METHODS. Seventeen children and young adults (mean [+/- SD] age, 14.1 +/- 3.7 years) undergoing regular peritoneal dialysis were randomly assigned to treatment with either aluminum hydroxide (n = 7; maximal dose, 30 mg per kilogram of body weight per day) or calcium carbonate (n = 10; dose range, 2.5 to 12 g per day, according to serum phosphorus levels). Aluminum retention was assessed by serial measurements of plasma aluminum, deferoxamine-infusion tests, and measurements of bone aluminum content during a mean (+/- SD) follow-up of 13 +/- 2 months. The evolution of bone disease was also evaluated. RESULTS. Plasma aluminum levels and the increment in plasma aluminum after infusion of deferoxamine increased from base-line values in the patients treated with aluminum hydroxide, and aluminum-related bone disease developed in one patient. Serum phosphorus levels remained higher and serum calcium levels lower in the patients receiving aluminum hydroxide than in those receiving calcium carbonate. The skeletal lesions of secondary hyperparathyroidism improved in 7 of 10 patients receiving calcium carbonate but persisted or progressed in 6 of 7 patients given aluminum hydroxide (P less than 0.025). CONCLUSIONS. Aluminum hydroxide is less effective than calcium carbonate as a phosphate-binding agent for the control of hyperphosphatemia and is associated with aluminum retention in children and young adults with chronic renal failure who are receiving dialysis therapy.

Source Information

Department of Pediatrics, UCLA School of Medicine.

This article has been cited by other articles:

• Kovesdy, C. P., Mehrotra, R., Kalantar-Zadeh, K. (2008). Battleground: Chronic Kidney Disorders Mineral and Bone Disease Calcium Obsession, Vitamin D, and Binder Confusion. CJASN 3: 168-173 [Abstract] [Full Text]  
• Salusky, I. B., Goodman, W. G., Sahney, S., Gales, B., Perilloux, A., Wang, H.-J., Elashoff, R. M., Juppner, H. (2005). Sevelamer Controls Parathyroid Hormone-Induced Bone Disease as Efficiently as Calcium Carbonate without Increasing Serum Calcium Levels during Therapy with Active Vitamin D Sterols. J. Am. Soc. Nephrol. 16: 2501-2508 [Abstract] [Full Text]  
• Salusky, I. B., Goodman, W. G. (2002). Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant 17: 336-339 [Abstract] [Full Text]  
• Gherardi, R. K., Coquet, M., Cherin, P., Belec, L., Moretto, P., Dreyfus, P. A., Pellissier, J.-F., Chariot, P., Authier, F.-J. (2001). Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 124: 1821-1831 [Abstract] [Full Text]  
• SALUSKY, I. B., GOODMAN, W. G. (2001). Adynamic Renal Osteodystrophy: Is There a Problem?. J. Am. Soc. Nephrol. 12: 1978-1985 [Full Text]  
• Salusky, I. B., Goodman, W. G. (2000). Managing phosphate retention: is a change necessary?. Nephrol Dial Transplant 15: 1738-1742 [Full Text]  
• Hanna, J. D., Foreman, J. W., Chan, J. C.M. (1991). Chronic Renal Insufficiency in Infants and Children. CLIN PEDIATR 30: 365-384  
• (1991). ALUMINUM HYDROXIDE IS POTENTIALLY DANGEROUS IN CHRONIC RENAL FAILURE. JWatch General 1991: 2-2 [Full Text]